Perspectives onIn VitrotoIn VivoExtrapolations

Abstract

Quantitative in vitro to in vivo extrapolation (QIVIVE) is broadly considered a prerequisite bridge from in vitro findings to a dose paradigm. Quality and relevance of cell systems are the first prerequisite for QIVIVE. Information-rich and mechanistic endpoints (biomarkers) improve extrapolations, but a sophisticated endpoint does not make a bad cell model a good one. The next need is reverse toxicokinetics (TK), which estimates the dose necessary to reach a tissue concentration that is active in vitro. The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) has created a roadmap for animal-free systemic toxicity testing, in which the needs and opportunities for TK are elaborated, in the context of different systemic toxicities. The report was discussed at two stakeholder forums in Brussels in 2012 and in Washington in 2013; the key recommendations are summarized herein. Contrary to common belief and the Paracelsus paradigm of everything is toxic, the majority of industrial chemicals do not exhibit toxicity. Strengthening the credibility of negative results of alternative approaches for hazard identification, therefore, avoids the need for QIVIVE. Here, especially the combination of methods in integrated testing strategies is most promising. Two further but very different approaches aim to overcome the problem of modeling in vivo complexity: The human-on-a-chip movement aims to reproduce large parts of living organism's complexity via microphysiological systems, that is, organ equivalents combined by microfluidics. At the same time, the Toxicity Testing in the 21st Century (Tox-21c) movement aims for mechanistic approaches (adverse outcome pathways as promoted by Organisation for Economic Co-operation and Development (OECD) or pathways of toxicity in the Human Toxome Project) for high-throughput screening, biological phenotyping, and ultimately a systems toxicology approach through integration with computer modeling. These 21st century approaches also require 21st century validation, for example, by evidence-based toxicology. Ultimately, QIVIVE is a prerequisite for extrapolating Tox-21c such approaches to human risk assessment.

Artificial Intelligence and Machine Learning in Computational Nanotoxicology: Unlocking and Empowering Nanomedicine

“…They have proved a promising potential and perspective to diminish animal testing during the development of future nanomedicine. [ 130 ] The algorithms in focus can generate a chemical map that contains the putative toxicology ingredients of thousands of compounds from databases with superior predictability. The algorithm can compare and replace an unknown chemical moiety within the map from thousands of databases available in nanochemistry, predicting the potential side effects and toxicity.…”

A Systematic Approach to Review of in vitro Methods in Brain Tumour Research (SAToRI-BTR): Development of a Preliminary Checklist for Evaluating Quality and Human Relevance

“…Perspectives on in vitro to in vivo extrapolations (Hartung, 2018) Y Hartung et al (2002) good cell culture practise ECVAM good cell culture practise task force report 1 (Hartung et al, 2002) Y Extending a risk-of-bias approach to address in vitro studies -a systematic review protocol (Rooney, 2015) Y…”

3S - Systematic, systemic, and systems biology and toxicology

“…As an example, in a recent organ-on-chip study (Kilic et al, 2016), mediator gradients were modeled computationally and and then verified experimentally. By parameterization of the experimental systems, we can also start to scale our systems virtually as a quantitative in vitro to in vivo extrapolation (QIVIVE) (Tsaioun et al, 2016; Hartung, 2018).…”